Methods used in clinical development of novel anti-asthma therapies
(2008) In Respiratory Medicine 102(3). p.332-338- Abstract
- In recent years, it has become increasingly important to get as much as possible information on clinical efficacy already in the early phases of drug development. For proof of concept (POC) studies testing novel anti-inflammatory drugs in asthma, there are several validated exacerbation models, inducing various aspects of the airway inflammation and airway responsiveness. The choice of the appropriate asthma model depends on the drug's targets within the inflammatory process. For adequate assessment of the drug's anti-inflammatory potential, it is crucial to choose adequate (surrogate) biomarkers. Ideally, these should include measures of airway response, central and peripheral airway inflammation and airway hyperresponsiveness. Overall,... (More)
- In recent years, it has become increasingly important to get as much as possible information on clinical efficacy already in the early phases of drug development. For proof of concept (POC) studies testing novel anti-inflammatory drugs in asthma, there are several validated exacerbation models, inducing various aspects of the airway inflammation and airway responsiveness. The choice of the appropriate asthma model depends on the drug's targets within the inflammatory process. For adequate assessment of the drug's anti-inflammatory potential, it is crucial to choose adequate (surrogate) biomarkers. Ideally, these should include measures of airway response, central and peripheral airway inflammation and airway hyperresponsiveness. Overall, there are validated non-invasive sampling techniques for the measurement of inflammatory markers in asthma that can be applied as outcome parameters in early clinical trials. If adequately implemented, these measurements can provide early indication of proof of pharmacological and potential therapeutic efficacy-even in first administration to humans. (C) 2007 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1191698
- author
- Diamant, Zuzana ; Boot, Diderik ; Kamerling, Ingrid and Bjermer, Leif LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- exacerbation models, asthma, early clinical trials, inflammometry
- in
- Respiratory Medicine
- volume
- 102
- issue
- 3
- pages
- 332 - 338
- publisher
- Elsevier
- external identifiers
-
- wos:000253637500003
- scopus:38749113369
- pmid:18061420
- ISSN
- 1532-3064
- DOI
- 10.1016/j.rmed.2007.10.018
- language
- English
- LU publication?
- yes
- id
- a4c344cd-0c9b-4544-aaca-7f4d741041f5 (old id 1191698)
- date added to LUP
- 2016-04-01 12:52:13
- date last changed
- 2022-01-27 08:01:36
@article{a4c344cd-0c9b-4544-aaca-7f4d741041f5,
abstract = {{In recent years, it has become increasingly important to get as much as possible information on clinical efficacy already in the early phases of drug development. For proof of concept (POC) studies testing novel anti-inflammatory drugs in asthma, there are several validated exacerbation models, inducing various aspects of the airway inflammation and airway responsiveness. The choice of the appropriate asthma model depends on the drug's targets within the inflammatory process. For adequate assessment of the drug's anti-inflammatory potential, it is crucial to choose adequate (surrogate) biomarkers. Ideally, these should include measures of airway response, central and peripheral airway inflammation and airway hyperresponsiveness. Overall, there are validated non-invasive sampling techniques for the measurement of inflammatory markers in asthma that can be applied as outcome parameters in early clinical trials. If adequately implemented, these measurements can provide early indication of proof of pharmacological and potential therapeutic efficacy-even in first administration to humans. (C) 2007 Elsevier Ltd. All rights reserved.}},
author = {{Diamant, Zuzana and Boot, Diderik and Kamerling, Ingrid and Bjermer, Leif}},
issn = {{1532-3064}},
keywords = {{exacerbation models; asthma; early clinical trials; inflammometry}},
language = {{eng}},
number = {{3}},
pages = {{332--338}},
publisher = {{Elsevier}},
series = {{Respiratory Medicine}},
title = {{Methods used in clinical development of novel anti-asthma therapies}},
url = {{http://dx.doi.org/10.1016/j.rmed.2007.10.018}},
doi = {{10.1016/j.rmed.2007.10.018}},
volume = {{102}},
year = {{2008}},
}